Literature DB >> 15899221

[Extra-cranial anaplastic oligoastrocytoma development from a low-grade glioma].

Jorge Molina Saera1, Angel Segura Huerta, Laura Palomar Abad, Alejandra Giménez Ortiz, José Ponce Lorenzo, Gaspar Reynés Muntaner.   

Abstract

Oligodendrogliomas are primary brain tumours derived from oligodendroglial cells, or precursors, and represent 2%-5% of brain tumours. This type of glioma has a favourable prognosis compared to other brain tumours. The treatment is multidisciplinary and is based on three therapeutic arms: surgery, radiotherapy and chemotherapy. We present a patient who had received treatment previously for a lowgrade glioma and who subsequently developed an anaplastic oligoastrocytoma in the same zone together with skull and extra-cranial involvement in the disease progression.

Entities:  

Mesh：

Year:  2005        PMID： 15899221     DOI： 10.1007/bf02708746

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  10 in total

1.  Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

Authors:  Y Ino; R A Betensky; M C Zlatescu; H Sasaki; D R Macdonald; A O Stemmer-Rachamimov; D A Ramsay; J G Cairncross; D N Louis
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

2.  Combined treatment modality for anaplastic oligodendroglioma: a phase II study.

Authors:  B Jeremic; Y Shibamoto; D Gruijicic; B Milicic; M Stojanovic; N Nikolic; A Dagovic; J Aleksandrovic
Journal:  J Neurooncol       Date:  1999-06       Impact factor: 4.130

Review 3.  Low-grade gliomas, mixed gliomas, and oligodendrogliomas.

Authors:  D R Macdonald
Journal:  Semin Oncol       Date:  1994-04       Impact factor: 4.929

4.  Radiation and chemotherapy improve outcome in oligodendroglioma.

Authors:  R R Allison; A Schulsinger; V Vongtama; T Barry; K H Shin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-01-15       Impact factor: 7.038

5.  Long-term outcome of low-grade oligodendroglioma and mixed glioma.

Authors:  J D Olson; E Riedel; L M DeAngelis
Journal:  Neurology       Date:  2000-04-11       Impact factor: 9.910

6.  Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

Authors:  O L Chinot; S Honore; H Dufour; M Barrie; D Figarella-Branger; X Muracciole; D Braguer; P M Martin; F Grisoli
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

7.  Oligodendroglioma: incidence and biological behavior in a defined population.

Authors:  S J Mørk; K F Lindegaard; T B Halvorsen; E H Lehmann; T Solgaard; R Hatlevoll; S Harvei; J Ganz
Journal:  J Neurosurg       Date:  1985-12       Impact factor: 5.115

8.  The treatment of anaplastic oligodendrogliomas and mixed gliomas.

Authors:  A P Kyritsis; W K Yung; J Bruner; M J Gleason; V A Levin
Journal:  Neurosurgery       Date:  1993-03       Impact factor: 4.654

9.  Oligodendrogliomas: the Mayo Clinic experience.

Authors:  E G Shaw; B W Scheithauer; J R O'Fallon; H D Tazelaar; D H Davis
Journal:  J Neurosurg       Date:  1992-03       Impact factor: 5.115

10.  Low grade supratentorial astrocytomas. Management and prognostic factors.

Authors:  P Janny; H Cure; M Mohr; N Heldt; F Kwiatkowski; J J Lemaire; R Plagne; R Rozan
Journal:  Cancer       Date:  1994-04-01       Impact factor: 6.860
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.